Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01583595
Recruitment Status : Completed
First Posted : April 24, 2012
Last Update Posted : April 4, 2013
Information provided by (Responsible Party):
Roberto P. Benzo, Mayo Clinic

Brief Summary:

Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate).

Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.

Condition or disease
Chronic Lung Disease Self-efficacy

Layout table for study information
Study Type : Observational
Actual Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease
Study Start Date : December 2011
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis) [ Time Frame: Day of enrollment. ]
    Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed.

Secondary Outcome Measures :
  1. Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor. [ Time Frame: 1 week ]
    Measure 4-meter gait speed during standardized 6 mintute walk test and compare to armband activity monitor results to determine predictive ability, if any, on PAL in people with chronic lung disease.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults with chronic lung disease

Inclusion Criteria:

  • Men and women 40 years and older
  • Diagnosis of any chronic lung disease as evidenced by pulmonary function testing completed within the prior 12 months
  • Able to walk independently and successfully complete the 6-minute walk assessment

Exclusion Criteria:

  • Unable to walk without assistance or complete the 6-minute walk assessment
  • Patients unable to comprehend and accurately respond to the study questionnaires either by written or spoken communication
  • Patients diagnosed with or treated for a lower respiratory tract infection or COPD exacerbation within the prior 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01583595

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Roberto P Benzo, M.D., MSc Mayo Clinic

Layout table for additonal information
Responsible Party: Roberto P. Benzo, Consultant Pulmonary and Critical Care Medicine, Mayo Clinic Identifier: NCT01583595    
Other Study ID Numbers: 11-008157
First Posted: April 24, 2012    Key Record Dates
Last Update Posted: April 4, 2013
Last Verified: March 2013
Keywords provided by Roberto P. Benzo, Mayo Clinic:
Chronic Lung Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases